Bought for $5million. IPO-ed at $4 billion. Miracle by a young 24-year old.
The famous 5-HT6 receptor agonist molecule discarded by big pharma, purchased for $5M and IPO'ed at $3B.
As oncology experts we want to discover our hidden gem in the Oncology Hematology (OncoHeme) arena .
Using our immense network of clinical trial specialists, we will develop that molecule through proof of concept.
But feel free to express interest over an email.